Global canine influenza vaccine market

Market Size and Trends

The global canine influenza vaccine market is estimated to be valued at USD 1,805.7 Mn in 2024, and is expected to reach USD 2,562.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.1% from 2024 to 2031.

Increasing pet adoption and rising awareness about animal health is expected to fuel the demand for canine influenza vaccines. Additionally, growth in R&D activities to develop effective and novel vaccines and rising government support for pet immunization will further aid market expansion. Vaccination has become an important practice to control the spread of canine influenza virus among the pet dog population. Wide distribution network of key players ensures broad availability and accessibility of vaccines which is also supporting the market growth.

Increasing Animal Healthcare Expenditure

Increasing animal healthcare expenditure is expected to drive the global canine influenza vaccine market growth over the forecast period. For instance, in May 2023, the North American Pet Health Insurance Association (NAPHIA) released its 2023 State of the Industry (SOI) report, indicating that the North American pet health insurance sector grew by 23.5% in In-Force GWP over 2022.

Market Concentration and Competitive Landscape

Growing Pet Ownership

Pet ownership has been steadily increasing, with more people considering their pets as family members and seeking quality healthcare for them. This trend has led to a rise in the demand for veterinary services and treatments, including for canine influenza vaccine. Pet owners are increasingly willing to spend on their pets' healthcare, driving the market for effective treatment. According to American Pet Products Association statistics, in April 2023, over the past three decades, pet ownership in the U.S. has experienced a notable surge. As of 2023, approximately 66% of households (equivalent to 86.9 million homes) are pet owners, compared to 56% in 1988, as indicated by pet ownership statistics. Pets hold a crucial role in their owners' lives, providing companionship and emotional support. Remarkably, 85% of dog owners and 76% of cat owners consider their pets to be integral members of their families.

Market Challenges – Stringent Regulations for Veterinary Vaccines

Regulatory authorities across countries have implemented strict norms and guidelines for the development, manufacturing, and approval of new veterinary vaccines to ensure safety, efficacy, and quality. Complying with these complex regulations involves extensive clinical trials, comprehensive documentation, and significant investments of both time and funds. This lengthens the overall product development lifecycle considerably and delays the market introduction of new canine influenza vaccines.

Market Opportunities – Increasing Awareness of Animal Health and Welfare

Increasing awareness of animal health and welfare and shifts in demographics and lifestyles leading to increased spending on pet healthcare. Various awareness programs are being organized in different regions to educate pet owners about animal disease diagnosis, treatment, and aftercare of canine atopic dermatitis which impacts the market positively. For instance, in May 2021, the American Pet Products Association (APPA) announced the launch of its “Pet Feels” campaign, the newest initiative for the association’s Pets Add Life (PAL) program.

Insights, By Vaccine Type: Safety and Efficacy Drives the Demand for Recombinant Vaccines

The vaccine type segment is sub-segmented into recombinant vaccines, inactivated vaccines, and others. The recombinant vaccines segment is expected to hold 47.1% of the market share in 2024. Recombinant vaccines are produced by using genetic engineering techniques to synthesize specific surface antigens of the virus in a host cell rather than by growing the live virus itself. This eliminates any risk of infecting dogs with a live virus. The fact that recombinant vaccines contain only the antigens needed to trigger an immune response against the virus makes them much safer than inactivated vaccines. They have a superior safety profile for puppies, elderly and immunocompromised dogs. Furthermore, recombinant vaccines produce strong protective immunity comparable to inactivated vaccines while avoiding any risks of reversion of live strains to a virulent form. Their consistent production process also ensures batch-to-batch consistency and quality which boosts owner and veterinarian confidence in these vaccines. Overall, the superior safety and efficacy of recombinant vaccines has enabled them to dominate the canine influenza vaccine market over the past decade.

Insights, By Virus Type: In-house infrastructure of Hospitals

Virus type segment is sub-segmented into H3N8 virus and H3N2 virus. The H3N8 virus segment is expected to hold 52.9% of the market share in 2024, due to its high prevalence globally. Canine influenza was first identified in 2004 in the U.S. caused by an influenza A H3N8 virus of equine origin. Since then, the H3N8 virus has caused epidemics among dogs across North America and has also spread to Asia and Europe. According to epidemiological studies, the H3N8 virus is now established in the canine population worldwide and is responsible for the majority of canine influenza cases. Its ability to spread rapidly among dogs coupled with lack of prior immunity has made repeated H3N8 outbreaks common. This sustained threat posed by the H3N8 strain to canine health and welfare has driven strong demand for H3N8 specific vaccines. These vaccines have played a pivotal role in controlling and preventing H3N8 epidemics, thus maintaining the dominant market share of the H3N8 virus segment.

Insights, By Distribution Channel: Public Health Priority Boosts Distribution through Public Channels

Distribution channel segment is sub-segmented into public and private. The public segment is expected to hold 64.3% of the market share in 2024, owing to the rising prioritization of canine influenza as a public health issue. Canine influenza viruses pose a zoonotic risk of interspecies transmission from dogs to humans. While human-to-human transmission has not been reported yet, the potential of the H3N8 virus to mutate and gain ability of efficient human transmission cannot be undertaken. This has pushed public health agencies to recognize canine influenza vaccination as a crucial aspect of pandemic preparedness planning. Consequently, many national and local governments now provide subsidized H3N8 vaccines through public veterinary clinics and mass vaccination drives. Community-wide vaccination programs target wide population coverage within a short time to curtail outbreaks. This strong public health emphasis has enabled greater accessibility and affordability of vaccines in public channels compared to private practices. The public health dimensions of canine influenza are thus a key market driver augmenting the distribution share of public channels.

Regional Insights

North America remains the dominant region in the global canine influenza vaccine market and is anticipated to hold 44.8% of the market share in 2024. The U.S. accounts for the bulk of the demand due to high pet adoption and awareness about canine health. Pet owners in the US are highly inclined towards vaccinating their dogs regularly due to ease of availability and recommendation by veterinarians. Major players, such as Zoetis, Merck, and Boehringer Ingelheim, have established robust distribution networks across veterinary clinics and pharmacies in the country to cater to the needs of dog owners. This widespread supply chain coupled with new product introductions at regular intervals has helped sustain the leadership position of North America in the global market.

The Asia Pacific region has emerged as the fastest growing market for canine influenza vaccines in recent years. Rising pet ownership in China and India due to changing socio-economic demographics is significantly driving the demand. With a growing middle class, more people are able to afford pet healthcare expenses. This provides avenues for vaccine companies to increase penetration in Asia Pacific through effective marketing strategies and tie-ups with local retail chains. However, lack of adequate veterinary infrastructure in rural areas acts as a barrier. But expanding veterinary clinics and hospitals in Tier I and Tier II cities are expected to boost the future sales potential. Further, regional vaccine manufacturers improving their R&D capabilities and production capacities will help Asia Pacific consolidate its status as a hotspot for high growth in the canine influenza vaccine market over the coming decade.

Market Report Scope

Key Developments

• In September 2022, Merck Animal Health, a part of Merck & Co., Inc., a pharmaceutical company, announced the launch of the first oral Bordetella bronchisepticaand canine parainfluenza virus vaccine with mucosal protection and easy oral administration. The vaccine has been shown to be effective for the vaccination of healthy dogs aged 7 weeks or older against canine parainfluenza virus and Bordetella bronchiseptica.
• In June 2021, Elanco, a U.S.-based pharmaceutical company, and Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, announced that the parties had entered a definitive agreement for Elanco to acquire KindredBio, a biopharmaceutical company focused on developing novel pet therapeutics based on validated human targets.

*Definition: Canine Influenza Vaccine helps to protect dogs from canine influenza virus infection. Canine influenza, also known as dog flu, is a contagious respiratory disease caused by an influenza virus that infects dogs. The vaccines available in this market help prevent dogs from contracting the H3N8 and H3N2 subtypes of canine influenza virus. The vaccines provide immunity and protection to dogs who are at risk of getting exposed to the influenza

Market Segmentation

• Vaccine Type Insights (Revenue, USD Mn, 2019 - 2031)
  • Recombinant Vaccines
  • Inactivated Vaccines
  • Others
• Virus Type Insights (Revenue, USD Mn, 2019 - 2031)
  • H3N8 virus
  • H3N2 virus
• Distribution Channel Insights (Revenue, USD Mn, 2019 - 2031)
  • Public
  • Private
• Regional Insights (Revenue, USD Mn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Zoetis Services LLC
  • Merck & Co., Inc.
  • Covetrus
  • CSL Limited
  • Boehringer Ingelheim Animal Health USA Inc.
  • Elanco